Psychedelic therapy pairs a controlled psychedelic substance with professional support before, during, and after the session — with evidence strongest for ketamine (FDA-approved as Spravato) and psilocybin (positive Phase 3 trials in 2025).
Psychedelic therapy is a fast-moving field, and the gap between what the research shows and what you can legally access today is large. This guide explains how the treatments work, what conditions they address, where you can get them right now, and what they realistically cost. It covers ketamine, psilocybin, MDMA, ayahuasca, and ibogaine in plain language.
Psychedelic therapy is a clinical model in which a patient takes a psychedelic or dissociative drug under medical supervision, with structured support before, during, and after the experience.
The term covers several different drugs and protocols. The most studied are ketamine (a dissociative), psilocybin (the active compound in “magic mushrooms”), and MDMA (an empathogen sometimes called Ecstasy). Each works differently in the brain, treats different conditions, and sits in a different legal category. What they share is the three-part model: preparation, the session itself, and integration — the therapeutic work you do after the drug wears off.
For a side-by-side breakdown of the two most available drugs, see our ketamine vs psilocybin guide. To explore each substance in depth, visit our guides on ketamine, psilocybin, MDMA, ayahuasca, and ibogaine.
Psychedelic therapy works through two channels: the biological effect of the drug on the brain, and the psychological processing that happens during and after the experience.
Classic psychedelics — psilocybin, LSD, DMT (in ayahuasca) — act primarily on the serotonin 5-HT2A receptor. Activating this receptor disrupts the brain’s default mode network, the system thought to maintain rigid patterns of thought. Neuroimaging studies show increased connectivity between brain regions that do not usually communicate strongly. Many researchers link this to the loosening of habitual, depressive, or anxious thought patterns.1
Ketamine works on a completely different system. It blocks the NMDA receptor in the glutamate pathway. This triggers a rapid release of brain-derived neurotrophic factor (BDNF) and promotes synaptogenesis — the growth of new synaptic connections. This is why ketamine can lift depression within hours, not weeks, unlike SSRIs.2 Ketamine is technically a dissociative anesthetic, not a classic psychedelic.
MDMA releases large amounts of serotonin, dopamine, and oxytocin. In therapy contexts, this reduces fear responses and increases feelings of trust, which researchers believe makes traumatic memories easier to process without re-traumatization. This is the basis for MAPS’s MDMA-assisted PTSD protocol.3
Most clinical protocols follow a three-stage model. In the preparation phase (one to three sessions), the clinician reviews your history, sets intentions, and builds trust. The dosing session takes place in a controlled environment — comfortable furniture, curated music, eye shades — with a trained guide present. The integration phase consists of follow-up therapy sessions to process what came up and apply insights to daily life.
Research consistently shows that integration is not optional. Patients who do follow-up therapy after ketamine or psilocybin sessions show better outcomes than those who do not. Our integration therapy guide covers this in detail.
Clinical research has targeted several mental health conditions, with different levels of evidence for each.
Treatment-resistant depression (TRD) — defined as depression that has not improved after at least two antidepressant trials — is the area with the strongest evidence across both ketamine and psilocybin.
For ketamine, the FDA approved Spravato (esketamine nasal spray) for TRD in 2019, and in January 2025 it became the first TRD treatment approved as a standalone therapy. Before the January 2025 update, Spravato required concurrent use of an oral antidepressant. That requirement has been removed. Patients can now use Spravato on its own — a meaningful change for people who cannot tolerate SSRIs or SNRIs.4
For psilocybin, COMPASS Pathways announced in 2025 that both of its Phase 3 trials of COMP360 psilocybin hit their primary endpoints for TRD, with statistically significant symptom reductions versus placebo.5 FDA review is ongoing. You cannot get psilocybin by prescription yet, but the trial results are the strongest the field has seen for a classic psychedelic.
MDMA-assisted therapy was studied specifically for PTSD in veterans, first responders, and survivors of sexual assault in the MAPS Phase 3 trials. Results showed that 67% of MDMA-treated participants no longer met PTSD diagnostic criteria after treatment, versus 32% in the placebo group.3 The FDA declined to approve the MAPS application in August 2024, citing concerns about trial design and data integrity, and requested an additional Phase 3 trial. Research continues.
The VA has funded ketamine research for veterans with PTSD and treatment-resistant depression. VA studies show rapid symptom relief in some patients, with ongoing work to determine optimal dosing and maintenance schedules.6 Ketamine is available at some VA medical centers off-label.
Psilocybin for generalized anxiety is in early-phase trials, with promising open-label data but no Phase 3 results yet. Ketamine is used off-label for anxiety at many clinics today.
Psilocybin has shown early promise for alcohol and tobacco use disorders. A 2022 trial published in JAMA Psychiatry found that two psilocybin sessions, combined with psychotherapy, significantly reduced heavy drinking days in adults with alcohol use disorder compared with diphenhydramine (an active placebo).7 Johns Hopkins reported that psilocybin-assisted therapy helped roughly 80% of participants quit smoking at a 12-month follow-up in a small pilot study.
Ibogaine, a West African plant-derived psychedelic, is being studied for opioid use disorder. A Stanford-led 2024 study of veterans found that ibogaine treatment led to significant reductions in opioid cravings and disability scores. Ibogaine is not FDA-approved and remains Schedule I in the US. See our ibogaine guide for details.
Psilocybin is in early clinical investigation for anorexia nervosa, one of the most treatment-resistant mental health conditions. A Phase 2 trial at Johns Hopkins and other sites is underway as of 2026, testing whether a single guided psilocybin session can loosen the rigid cognitive patterns associated with anorexia. Results are not yet available.
Psilocybin produces lasting reductions in anxiety and depression in patients facing terminal illness. Johns Hopkins researchers found that one or two high-dose psilocybin sessions, combined with therapy, produced significant decreases in anxiety and depression that persisted at a six-month follow-up in patients with life-threatening cancer diagnoses.8 This is one of the most replicated findings in the field.
Legal status varies significantly by drug, and the gap between research findings and what you can actually access today is wide.
Ketamine is Schedule III under the Controlled Substances Act. Physicians can prescribe it for any use. Off-label IV ketamine infusions are available at hundreds of clinics nationwide. Spravato is specifically approved for TRD and major depressive disorder with acute suicidal ideation, and must be administered in a certified healthcare setting.
Psilocybin is Schedule I federally, meaning it has no accepted medical use under federal law. Possession and distribution are federal crimes. However, two states have created state-level regulated frameworks that coexist with federal law (similar to cannabis):
MDMA is Schedule I. It is not FDA-approved as a therapeutic. Access is limited to ongoing clinical trials.
Ayahuasca contains DMT, which is Schedule I. A handful of churches operate under claimed religious exemptions (following the Gonzales v. O Centro Espirita Beneficente Uniao do Vegetal Supreme Court ruling), but commercial therapy use is not legal. See our ayahuasca guide.
As of mid-2026, only Oregon and Colorado have active, regulated psilocybin programs. Several other states — including California, Washington, and Vermont — have passed or are pursuing decriminalization measures, but decriminalization is not the same as a legal therapy program. Ketamine is legal to prescribe in all 50 states. No other psychedelic has a state-level legal therapy framework in the US as of this writing.
There is no firm federal timeline. Psilocybin would need FDA approval and a DEA rescheduling to become prescription-accessible. Given the COMPASS Phase 3 results in 2025, an FDA application is likely in 2026 or 2027. The rescheduling process typically takes one to three years after FDA approval. Conservative estimates put nationwide psilocybin therapy access at 2028–2030. MDMA faces a longer path given the 2024 FDA rejection. Ketamine is available today, nationwide.
Insurance coverage depends entirely on which drug and delivery model you use.
Spravato (esketamine) is covered by many major insurance plans, including Blue Cross Blue Shield, Aetna, and UnitedHealthcare, when prescribed for FDA-approved indications (TRD or MDD with acute suicidal ideation). Coverage requires prior authorization in most cases, and the drug must be administered in a certified office or clinic. Your out-of-pocket cost depends on your plan’s deductible and copay structure.
Off-label ketamine (IV infusions, lozenges, intramuscular) is almost never covered by insurance because it is not FDA-approved for any psychiatric indication. Costs run roughly $400–$800 per IV session. Telehealth ketamine providers offering at-home lozenges typically charge $150–$400 per month for ongoing treatment. Some providers offer financing plans.
Psilocybin is not covered by insurance anywhere in the US. The Oregon and Colorado regulated programs are entirely out of pocket. A single psilocybin session in Oregon — including the facilitator’s time, preparation, and follow-up — typically costs $1,000–$3,500.9 Some service centers offer sliding-scale pricing.
HSA and FSA funds can be used for qualified medical expenses. Off-label ketamine infusions at a licensed medical facility may qualify. Consult your HSA/FSA plan administrator before assuming eligibility. Oregon psilocybin sessions at a licensed service center likely do not qualify under current IRS guidance, given the federal Schedule I status.
Clinical trials for all of these drugs are free to participants. If you qualify and can access a trial site, this is the lowest-cost path to psilocybin or MDMA. See our clinical trial finder.
Psychedelic therapy is generally safe when administered by trained professionals who screen patients properly — but it is not risk-free, and it is not appropriate for everyone.
The most common adverse effects across ketamine and psilocybin are transient: nausea, dizziness, elevated blood pressure, and temporary anxiety or disorientation during the session. These are manageable in a supervised setting and resolve when the drug wears off.
Serious adverse events are rare in clinical trial settings. The risk of serious adverse events increases when drugs are used without medical screening, outside a supervised setting, or combined with contraindicated medications.
The honest answer is: it depends on the drug, the condition, and the quality of care — and for most applications, we still have limited long-term real-world data outside of clinical trials.
Strongest evidence (FDA-approved): Spravato (esketamine) for treatment-resistant depression. Multiple randomized controlled trials support efficacy. The January 2025 monotherapy approval reflects the FDA’s confidence in the data.
Very promising (Phase 3 data, no FDA approval yet): Psilocybin for treatment-resistant depression. COMPASS Pathways’ two Phase 3 trials hit primary endpoints in 2025. If the FDA application clears review, psilocybin could become a prescription treatment within a few years.
Promising Phase 2, awaiting Phase 3: Psilocybin for alcohol use disorder and end-of-life anxiety, ketamine for PTSD, MDMA for PTSD (pending a new Phase 3 after the 2024 FDA rejection).
Early or experimental: Psilocybin for eating disorders, ibogaine for opioid use disorder, ayahuasca for depression. Interesting early signals, but not yet enough controlled trial data to draw firm conclusions.
Importantly, none of these are cures. Most trials show significant response rates — not universal response. Durability varies. Ketamine’s antidepressant effect often fades after days to weeks without maintenance sessions. Psilocybin’s effects may last months from a single dose, but the data on long-term outcomes is still limited. A responsible provider will set realistic expectations before you start.
Your realistic options today depend on which treatment fits your condition and your location.
Ketamine is the most accessible path. Options include:
To access legal psilocybin therapy, you must visit a licensed service center in Oregon or Colorado. No referral or prescription is needed. Steps:
Many people travel from other states for this access. Find a licensed psilocybin service center.
If you want access to psilocybin, MDMA, or ibogaine outside of a legal state program, a clinical trial is the safest and most legal option. Participation is usually free. You must meet eligibility criteria (often a specific diagnosis and treatment history). Sites are concentrated in major research cities. Search open psychedelic therapy trials.
Use our which psychedelic quiz to get a starting point based on your condition and goals. If you are specifically exploring options for depression, our depression treatment path tool compares psychedelic options against conventional treatments side by side.
If you are a clinician or considering a career in this field, our guide on how to become a psychedelic therapist covers licensing requirements, training programs, and the Oregon lay-facilitator pathway.
Psychedelic therapy uses a controlled psychedelic substance — most commonly ketamine, psilocybin, or (in clinical trials) MDMA — combined with professional preparation, a supervised dosing session, and follow-up integration support. The substance is not the treatment by itself; the structured clinical context is essential. Ketamine is the only form legally available nationwide today, as esketamine (Spravato) is FDA-approved and off-label ketamine is widely prescribed.
The strongest evidence is for treatment-resistant depression and PTSD. Ketamine (as Spravato) is FDA-approved for treatment-resistant depression. Psilocybin had two positive Phase 3 trials for treatment-resistant depression in 2025. MDMA-assisted therapy showed positive Phase 3 results for PTSD but received an FDA complete response letter in 2024 requesting additional data. Addiction, end-of-life anxiety, and eating disorders are active research areas with promising early data but no FDA approval yet.
It depends on the substance. Ketamine therapy is legal in all 50 states — esketamine (Spravato) is FDA-approved, and off-label ketamine is widely prescribed by clinics and telehealth providers. Psilocybin therapy is legal only at licensed service centers in Oregon (Measure 109) and Colorado (Proposition 122). MDMA therapy is not FDA-approved and is available only through clinical trials. All other psychedelics remain Schedule I federally.
Spravato (esketamine) is the only form with meaningful insurance coverage. Many major insurers — including some Blue Cross, Aetna, and UnitedHealthcare plans — cover Spravato for patients who meet the treatment-resistant depression criteria. Off-label IV or sublingual ketamine is usually out of pocket, running $400 to $800 per infusion. Psilocybin therapy in Oregon or Colorado is not covered by insurance, typically costing $1,000 to $3,500 per session. Clinical trials are generally free to participants.
When administered by a licensed provider with proper screening, serious adverse events are uncommon. The main contraindications are a personal or family history of schizophrenia or bipolar I disorder (risk of psychosis), uncontrolled cardiovascular disease (ketamine raises blood pressure temporarily), and certain drug combinations (SSRIs with ayahuasca's MAOI component can cause serotonin syndrome). Never attempt psychedelic therapy without a licensed provider, regardless of how the substance was obtained.
A firm nationwide timeline does not exist. Ketamine is already legal everywhere. Psilocybin may eventually receive FDA approval — COMPASS Pathways submitted its New Drug Application based on its 2025 Phase 3 data — but the review process typically takes 12 to 24 months from submission, and approval is not guaranteed. MDMA-assisted therapy must address the FDA's 2024 complete response letter before resubmission. State-level programs in Oregon and Colorado are already operating for psilocybin.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.